PHM 431 exam 3 final questions with
complete solutions12
amphetamine - ANSWERS-not a substrate for MAO but it is for VMAT
stored in vesicles as a false transmitter
false transmitter - ANSWERS-Released as a transmitter but it cannot activate receptors
NE B receptor - ANSWERS-stimulatory G protein receptor, activates Gs, which activates
adenylate cyclase
Gs - ANSWERS-activates adenylate cyclase
NE a receptor - ANSWERS-produces Gi, which inhibits adenylate cyclase
D1 dopamine receptir - ANSWERS-activates Gs which causes an excitatory response by
activating adenylate cyclase
D2 dopamine receptor - ANSWERS-activates Gi which causes an inhibitory response
Pseudoephedrine - ANSWERS-the active ingredient in sudafed and other nasal decongestants. it
is the stereoisomer of ephedrine
Ephedrine/Pseudoephedrine - ANSWERS-the methyl group protects from oxidation and makes
these compounds orally active
not metabolites for MAO or COMT because the hydroxyl groups are missing
, Pseudoephrine to methamphetamine - ANSWERS-need LiAlH4 or Pd/C
requires hydrogenation of OH groups and dehalogenation
euphoric effects of amphetamine - ANSWERS-mediated via activation of the mesolimbic
dopamine system. Causes dopamine release in the nucleus accumbens
drug wanting - ANSWERS-correlated with personality traits of exploratory excitability and
novelty seeking
amphetamine and satiety - ANSWERS-causes CART peptides to be induced, CART peptides
inhibit feeding behavior caused by neuropeptide Y
increase in NPY - ANSWERS-increase in feeding
CART peptides - ANSWERS-found in the mesolimbic dopamine system and the hypothalamus
contribute to the appetite suppressing effects of amphetamine
5q13-14 locus - ANSWERS-a site that has been associated with susceptibility to obesity
ritalin - ANSWERS-large bulky substituents make it orally active
increases activity in ventral tegmental area
increases dopamine release in frontal cortex and caudate putamen
helps to focus patient on decision making
MDMA side effects - ANSWERS-hyperthermia and hyponatremia
complete solutions12
amphetamine - ANSWERS-not a substrate for MAO but it is for VMAT
stored in vesicles as a false transmitter
false transmitter - ANSWERS-Released as a transmitter but it cannot activate receptors
NE B receptor - ANSWERS-stimulatory G protein receptor, activates Gs, which activates
adenylate cyclase
Gs - ANSWERS-activates adenylate cyclase
NE a receptor - ANSWERS-produces Gi, which inhibits adenylate cyclase
D1 dopamine receptir - ANSWERS-activates Gs which causes an excitatory response by
activating adenylate cyclase
D2 dopamine receptor - ANSWERS-activates Gi which causes an inhibitory response
Pseudoephedrine - ANSWERS-the active ingredient in sudafed and other nasal decongestants. it
is the stereoisomer of ephedrine
Ephedrine/Pseudoephedrine - ANSWERS-the methyl group protects from oxidation and makes
these compounds orally active
not metabolites for MAO or COMT because the hydroxyl groups are missing
, Pseudoephrine to methamphetamine - ANSWERS-need LiAlH4 or Pd/C
requires hydrogenation of OH groups and dehalogenation
euphoric effects of amphetamine - ANSWERS-mediated via activation of the mesolimbic
dopamine system. Causes dopamine release in the nucleus accumbens
drug wanting - ANSWERS-correlated with personality traits of exploratory excitability and
novelty seeking
amphetamine and satiety - ANSWERS-causes CART peptides to be induced, CART peptides
inhibit feeding behavior caused by neuropeptide Y
increase in NPY - ANSWERS-increase in feeding
CART peptides - ANSWERS-found in the mesolimbic dopamine system and the hypothalamus
contribute to the appetite suppressing effects of amphetamine
5q13-14 locus - ANSWERS-a site that has been associated with susceptibility to obesity
ritalin - ANSWERS-large bulky substituents make it orally active
increases activity in ventral tegmental area
increases dopamine release in frontal cortex and caudate putamen
helps to focus patient on decision making
MDMA side effects - ANSWERS-hyperthermia and hyponatremia
